349 related articles for article (PubMed ID: 29659569)
1. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
Paulo P; Maia S; Pinto C; Pinto P; Monteiro A; Peixoto A; Teixeira MR
PLoS Genet; 2018 Apr; 14(4):e1007355. PubMed ID: 29659569
[TBL] [Abstract][Full Text] [Related]
2. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
4. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
5. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
6. A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.
Kote-Jarai Z; Jugurnauth S; Mulholland S; Leongamornlert DA; Guy M; Edwards S; Tymrakiewitcz M; O'Brien L; Hall A; Wilkinson R; Al Olama AA; Morrison J; Muir K; Neal D; Donovan J; Hamdy F; Easton DF; Eeles R; ;
Br J Cancer; 2009 Jan; 100(2):426-30. PubMed ID: 19127258
[TBL] [Abstract][Full Text] [Related]
7. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies.
Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J
Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
9. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2.
Eoh KJ; Kim JE; Park HS; Lee ST; Park JS; Han JW; Lee JY; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ
Cancer Res Treat; 2018 Jul; 50(3):917-925. PubMed ID: 29020732
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
11. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
12. Rare
Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
[TBL] [Abstract][Full Text] [Related]
13. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
14. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354
[TBL] [Abstract][Full Text] [Related]
15. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.
Lewis AG; Flanagan J; Marsh A; Pupo GM; Mann G; Spurdle AB; Lindeman GJ; Visvader JE; Brown MA; Chenevix-Trench G;
Breast Cancer Res; 2005; 7(6):R1005-16. PubMed ID: 16280053
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P
Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731
[TBL] [Abstract][Full Text] [Related]
17. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
[TBL] [Abstract][Full Text] [Related]
18. Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
Beebe-Dimmer JL; Zuhlke KA; Johnson AM; Liesman D; Cooney KA
Prostate; 2018 Apr; 78(5):321-326. PubMed ID: 29356034
[TBL] [Abstract][Full Text] [Related]
19. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
[TBL] [Abstract][Full Text] [Related]
20. Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients.
Paulo P; Cardoso M; Brandão A; Pinto P; Falconi A; Pinheiro M; Cerveira N; Silva R; Santos C; Pinto C; Peixoto A; Maia S; Teixeira MR
Genes Chromosomes Cancer; 2023 Dec; 62(12):710-720. PubMed ID: 37436117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
